Table 1.
Baseline demographic and clinical characteristics.
| VARIABLE | Patients Treated with Diflunisal n = 16 |
|---|---|
| Age (years, IQR) | 82.2 (78.5–87.0) |
| Male/Female | 13/3 |
| ATTRm/ATTRwt | 2/14 |
| Comorbidities | |
| Smoker (%) | 37.5 |
| Hypertension (%) | 75.0 |
| Diabetes mellitus (%) | 12.5 |
| Dyslipidemia (%) | 75.0 |
| Obesity (%) | 18.8 |
| Coronary artery disease (%) | 11.1 |
| Cerebrovascular disease (%) | 6.3 |
| Previous heart failure (%) | 37.5 |
| Atrial fibrillation (%) | 50 |
| Chronic kidney disease (%) | 50.0 |
| Carpal tunnel syndrome (%) | 18.8 |
| Lumbar canal stenosis (%) | 18.8 |
| Polyneuropathy (%) | 12.5 |
| Previous Medical Treatment | |
| Antiagregants (%) | 6.3 |
| Anticoagulants (%) | 43.8 |
| SLT2i (%) | 31.3 |
| ACEi (%) | 18.8 |
| ARB (%) | 18.8 |
| MRA (%) | 31.3 |
| Beta-blockers (%) | 31.3 |
| Antiarrhythmic drugs (%) | 12.5 |
| Digoxin (%) | 0 |
Quantitative data are displayed as median (IQR = interquartile range), and qualitative variables are presented as percentages. ACEi = angiotensin-converting enzyme inhibitors; ARB = angiotensin receptor blockers; MRA = mineraloid receptor antagonists; SLT2i = sodium-glucose cotransporter 2 inhibitors.